

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Company 2023/09/22 22:00:00

Price
824.84
USD

Difference  0.18%(1.46)

REGENERON



Contact Details

REGENERON PHARMACEUTICALS INC.
--
777 Old Saw Mill River Road
10591-6707 Tarrytown

Tel: +1-914-847-7000
Fax: +
Web: <http://www.regeneron.com>
E-mail: -

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as Velocimmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	15,884,100,000		14,014,900,000		9,779,100,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	13,388,600,000		11,419,900,000		7,384,200,000	
Equity capital of a company		22,664,000,000		18,768,800,000		11,025,300,000
Cash and cash equivalents	3,105,900,000		2,885,600,000		2,193,700,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,141,300,000		3,932,500,000		2,697,400,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,467,400,000		2,733,500,000		3,440,600,000
Different income		-		-		-
Other liabilities		707,800,000		753,500,000		744,900,000
Total assets	29,272,700,000	29,272,700,000	25,434,800,000	25,434,800,000	17,163,300,000	17,163,300,000

Balance notes

	2022	2021	2020
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	11,851	10,368	9,123
Equity ratio	77.42%	73.79%	64.24%
Debt-equity ratio	29.16%	35.52%	55.67%

Others

	2022	2021	2020
Tax Expense Rate	10.71%	13.41%	7.80%

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

Income statement

	2022	2021	2020
Turnover	12,172,900,000	16,071,700,000	8,497,100,000
Net income	4,338,400,000	8,075,300,000	3,513,200,000
EBIT	4,450,250,930	8,776,013,430	3,617,085,690
Operating income before taxes	4,858,800,000	9,325,800,000	3,810,400,000
Cash Flow	5,014,900,000	7,081,300,000	2,618,100,000
Net interest income	100,700,000	-57,300,000	-56,900,000
Research and development expenses	3,056,100,000	2,621,900,000	2,499,100,000
Income taxes	520,400,000	1,250,500,000	297,200,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	960,705	1,449,832	871,132

Board of Directors

Members of Management Board

George Yancopoulos	Chairman of Board of Directors
Bonnie Bassler	Member of Board of Directors
Craig Thompson	Member of Board of Directors
David Schenkein	Member of Board of Directors
Huda Zoghbi	Member of Board of Directors
Joseph Goldstein	Member of Board of Directors
Kathryn Guarini	Member of Board of Directors
Michael Brown	Member of Board of Directors
N. Coles	Member of Board of Directors
Arthur Ryan	Member of Board of Directors
Christine Poon	Member of Board of Directors
George Sing	Member of Board of Directors
Leonard Schleifer	Chairman of Managing Board
Alan Shuldiner	Member of Executive Committee
Andrew Murphy	Member of Executive Committee
Johnathan Lancaster	Member of Executive Committee
Kerry Reinertsen	Member of Executive Committee
Ned Braunstein	Member of Executive Committee
Neil Stahl	Member of Executive Committee
Beth Holly	Member of Executive Committee
Bob McCowan	Member of Executive Committee
Christopher Fenimore	Member of Executive Committee
Daniel van Plew	Member of Executive Committee
Gerald Underwood	Member of Executive Committee
Joseph LaRosa	Member of Executive Committee